ViiV Healthcare press release
London, 17 February 2026 – ViiV Healthcare today announced data presentations from its innovative HIV treatment and prevention portfolio and integrase inhibitor (INSTI)-led pipeline at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado from 22-25 February.
— First-in-human data for long-acting formulations of VH184, the first third-generation integrase inhibitor, and early data for capsid inhibitor VH499 to be presented, highlighting progress in ViiV’s ultra long-acting pipeline
— 12-month data to be presented for investigational lotivibart (N6LS) + cabotegravir long-acting, evaluating feasibility of ultra long-acting dosing intervals
— Clinical data and real-world evidence from ViiV’s innovative portfolio include insights for established INSTI-based long-acting Cabenuva (cabotegravir + rilpivirine LA) and 2-drug regimen Dovato (dolutegravir/lamivudine)
Read the full press release here.
Source : ViiV Healthcare
Related HIV and Co-Infections News
-
HIV i-Base: HPV and anal cancer in HIV+ gay men: new campaign in Manchester: anal HPV in gay men on PrEP
-
[Press release] Gilead to present new HIV treatment and prevention data at CROI 2026, with a focus on expanding options
-
WHO: Statement on the planned hepatitis B birth dose vaccine trial in Guinea-Bissau
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.